Vertex gives update on CF triple combos, reports earnings

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Wednesday it expects to submit an NDA by mid-2019 for a triple combination therapy to treat cystic fibrosis. The company is evaluating two different triple combinations -- VX-445

Read the full 333 word article

User Sign In